Stage IV Ovarian Cancer Clinical Trial
Official title:
Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis
This research study is studying a possible test which may help doctors diagnose women with ovarian cancer.
This research study is a Feasibility Study, to try to evaluate whether or not culdocentesis
can detect tumor associated cell free DNA. Although this is the first time investigators are
using this type of procedure to detect cell free DNA, culdocentesis is not a new procedure.
It used to be done routinely in the past to examine pelvic fluid. The investigator's goal is
to develop a test to detect ovarian cancer in women before they develop any signs or symptoms
of the disease. Currently, there is no screening test for ovarian cancer.
This study uses a technique called "culdocentesis" to detect DNA released by ovarian cancer
cells into pelvic fluid. During culdocentesis, a small needle is inserted through the vagina
into an empty space between the uterus and the rectum called the "cul-de-sac." Fluid is
withdrawn from this space and sent for analysis. Culdocentesis is a technique that has been
used for many years to examine pelvic fluid and determine its composition, but it has not
previously been studied as a technique for examining cell-free DNA to detect ovarian cancer.
The investigators suspect that this may be a useful way to detect cell-free DNA from ovarian
cancer cells because the ovaries are very close to the cul-de-sac space.
In this study, the investigators will compare our ability to detect cell-free DNA in fluid
from the cul-de-sac with our ability to detect cell-free DNA from a vaginal swab (similar to
a Pap smear), a blood test, and in the tissue specimens collected at the time of surgery. The
investigators are hoping to learn from this study whether developing a cell-free DNA test to
screen for ovarian cancer involving culdocentesis would be an effective strategy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01010126 -
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
|
Phase 2 | |
Terminated |
NCT00899093 -
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
|
||
Completed |
NCT00301756 -
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
|
Phase 2 | |
Completed |
NCT00262847 -
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
|
Phase 3 | |
Recruiting |
NCT01000259 -
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
|
N/A | |
Completed |
NCT00066456 -
Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
|
Phase 1 | |
Withdrawn |
NCT00551265 -
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
|
N/A | |
Completed |
NCT03188432 -
Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 2 | |
Completed |
NCT03297489 -
Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer
|
Early Phase 1 | |
Withdrawn |
NCT00053235 -
Research Study in Patients With Advanced Ovarian Epithelial Cancer
|
N/A | |
Completed |
NCT00194714 -
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
|
Phase 1/Phase 2 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05659381 -
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
|
Phase 3 | |
Terminated |
NCT00003532 -
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer
|
Phase 2 | |
Completed |
NCT01551745 -
Salvage Ovarian FANG™ Vaccine + Bevacizumab
|
Phase 2 | |
Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06315270 -
To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
|
||
Withdrawn |
NCT02872519 -
PET Imaging of Ovarian Carcinoma With 18F-FSPG
|
Early Phase 1 | |
Withdrawn |
NCT02567396 -
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
|
Phase 1 | |
Withdrawn |
NCT02470559 -
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
|
Phase 1 |